A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Clinical trial NCT07027514 · RECRUITING
Trial details
- NCT number
- NCT07027514
- Sponsor
- Ankyra Therapeutics, Inc
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-22
- Primary completion
- 2027-06-30
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.